ld Sleep Congress 2025; 2025 Sep 8; Singapore.

Sivam S, Hsiao S, Du Y, et al. Effect of the Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) on Quality of Life in Individuals with NT1 over 21 weeks. Presented at: World Sleep Congress 2025; 2025 Sep 8; Singapore.

Barateau L, Arnulf I, Dauvilliers, Y, et al. Effect of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) on the Severity of Symptoms in Individuals With Narcolepsy Type 1: Results From Two Phase 3 Studies. Presented at: World Sleep Congress 2025; 2025 Sep 8; Singapore.









Contacts


Media Contacts:

Japanese Media
Yuko Yoneyama
yuko.yoneyama@takeda.com

U.S. and International Media
Rachel Wallace
rachel.wallace2@takeda.com





=*=*=*=*=*=
当前为第18/18页
上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页